A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)

Ascenta Therapeutics0 sites220 target enrollmentOctober 2007

ConditionsHormone Refractory Prostate Cancer

InterventionsAT-101, prednisone and docetaxel placebo, prednisone and docetaxel

DrugsAT-101, prednisone and docetaxel placebo, prednisone and docetaxel

Overview

Phase: Phase 2
Intervention: AT-101, prednisone and docetaxel
Conditions: Hormone Refractory Prostate Cancer
Sponsor: Ascenta Therapeutics
Enrollment: 220
Primary Endpoint: To evaluate and compare the two treatment arms with respect to overall survival (OS)
Status: Completed
Last Updated: 15 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Similar Trials

Overview

Brief Summary

This is a randomized, double-blind, placebo-controlled, multinational Phase 2 study to evaluate and compare oral AT-101 in combination with docetaxel and prednisone versus docetaxel and prednisone plus placebo in the treatment of chemotherapy-naïve metastatic hormone-refractory prostate cancer, who have received hormonal therapy but not chemotherapy.

Detailed Description

Further Study Details provided by Ascenta.

Registry

clinicaltrials.gov

Start Date

October 2007

End Date

September 2010

Last Updated

15 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Ascenta Therapeutics

Eligibility Criteria

Inclusion Criteria

•Males age ≥ 18 years with histologically confirmed adenocarcinoma of the prostate, which is now metastatic (e.g. any T, any N, M1a-c) based on bone scan, CT scan, or MRI scan.
•Progression of disease despite androgen deprivation (androgen ablation or surgical castration) and anti-androgen withdrawal as documented by one or more of the following.
•Progression of measurable disease per RECIST
•Bone scan progression, defined as the appearance of ≥ 2 new lesions on bone scan, attributable to prostate cancer
•Rising PSA, as defined by increasing levels on at least two consecutive assessments, following a prior assessment taken as a reference value, where all of the following are met:
•The assessments are at least one week apart, with the first assessment at least one week later than the reference value
•Progressive increase in the two assessments after the reference value, without an intervening decrease between assessments.
•The last value prior to study entry is ≥ 2 ng/mL
•Serum testosterone level ≤ 50 ng/dL post orchiectomy or while maintained on continuous or intermittent medical androgen suppression with a LHRH agonist or antagonist.
•At least 2 weeks since ketoconazole or systemic steroids (any dose); 2 weeks since prior flutamide, megestrol, or aminoglutethimide; and at least 2 weeks since prior bicalutamide or nilutamide

Exclusion Criteria

•Received prior chemotherapy (including estramustine phosphate \[Estracyt\]) for HRPC. Adjuvant chemotherapy (including docetaxel) is allowed provided that progression of disease occurred ≥ 6 months after the completion of adjuvant therapy.
•Patients must not be receiving concurrent anti-androgen hormonal therapy for HRPC (LHRH directed therapies are acceptable to maintain castrate levels of testosterone).
•Treatment with monoclonal antibody (e.g., VEGF targeting antibody) or prostate cancer vaccine within 45 days prior to the first dose of study treatment. Acute toxicities from prior therapy must have resolved to Grade ≤
•Known history of or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis
•Active secondary malignancy or history of other malignancy within the last 5 years
•Prior history of radiation therapy to ≥ 30% of the bone marrow
•Peripheral neuropathy of ≥ Grade 2
•Patients with malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel are excluded. Subjects with ulcerative colitis, inflammatory bowel disease, or partial or complete small bowel obstruction are also excluded.
•Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification
•Known active symptomatic fungal, bacterial and/or viral infection including active HIV. Note: screening for viruses is not required.

Arms & Interventions

1

AT-101, prednisone and docetaxel

Intervention: AT-101, prednisone and docetaxel

2

Placebo, prednisone and docetaxel

Intervention: placebo, prednisone and docetaxel

Outcomes

Primary Outcomes

To evaluate and compare the two treatment arms with respect to overall survival (OS)

Time Frame: 33 months

Secondary Outcomes

To evaluate and compare progression-free survival (PFS) in men with chemotherapy-naïve metastatic HRPC treated with AT-101 in combination with docetaxel and prednisone versus docetaxel and prednisone plus placebo.(33 months)
To determine the toxicities associated with oral AT-101 administered in combination with docetaxel and prednisone.(28 months)
To evaluate PSA and objective tumor response rate.(28 months)